Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. (Nasdaq: CUE) is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts and focused on developing injectable biologics that selectively engage disease-specific T cells. News about Cue Biopharma often centers on its Immuno-STAT platform, clinical data from its CUE-100 series programs, and progress in autoimmune disease and oncology.
Investors and followers of CUE stock can use this page to review company press releases and third-party coverage related to Cue Biopharma’s pipeline. Typical updates include clinical trial readouts for CUE-101 in HPV16+ head and neck cancer and CUE-102 in WT1-expressing tumors, as well as developments around CUE-401, the company’s lead autoimmune asset designed to promote regulatory T cell–mediated tolerance.
News flow also highlights Cue Biopharma’s strategic collaborations and corporate milestones. Examples include agreements with Boehringer Ingelheim for CUE-501, a differentiated B cell depletion therapy for autoimmune and inflammatory diseases, and a collaboration and license agreement with ImmunoScape to advance a Seed-and-Boost cell therapy approach for solid tumors using the CUE-100 series. Financial updates, such as quarterly results, collaboration revenue disclosures and public equity offerings under the company’s shelf registration statement, are also common topics.
By following this CUE news feed, readers can track regulatory interactions, investigator-sponsored trials, leadership transitions, licensing deals and financing activities that may influence Cue Biopharma’s development trajectory. Bookmark this page to quickly access the latest headlines and historical announcements related to Cue Biopharma and its Immuno-STAT-based biologics.
Cue Biopharma (Nasdaq: CUE) appointed Lucinda Warren as interim president and chief executive officer, effective March 27, 2026, after Usman Azam stepped down effective March 26, 2026. The board credited Ms. Warren with recent deal execution, including recovery of CUE-401 rights and collaborations with Boehringer Ingelheim and ImmunoScape.
Ms. Warren said she will focus on advancing CUE-401 into the clinic by the second half of 2026; she has 30+ years of global pharma and biotech experience and prior business development leadership at Johnson & Johnson.
Cue Biopharma (Nasdaq: CUE) will host a virtual R&D Day on April 7, 2026 at 10:00 AM EDT to present research on its lead asset, CUE-401, aimed at regulating proinflammatory mechanisms and promoting Treg differentiation for autoimmune and inflammatory diseases.
Key Opinion Leaders Richard DiPaolo, PhD, and Jonathan Kay, MD, will join company management for presentations, followed by a live Q&A. A live and archived webcast will be available on the company website and will be archived for 30 days.
Cue Biopharma (Nasdaq: CUE) reported Q4 and full-year 2025 results on March 16, 2026, highlighting a strategic collaboration with ImmunoScape, progress on lead autoimmune candidate CUE-401, and financing actions.
Key metrics: Q4 collaboration revenue of $21.9M, full-year collaboration revenue of $27.5M, cash and equivalents of $27.1M at year-end, net loss for 2025 of $26.6M, and net proceeds of $10.2M from a public offering. The company received $9.5M of a $15M upfront payment and obtained a 40% equity stake in ImmunoScape.
Cue Biopharma (Nasdaq: CUE) will present new in vitro data for lead asset CUE-401 at the World Immune Regulation Meeting (WIRM) in Davos, March 11–14, 2026.
The poster (Session P5) on March 12, 2026 highlights CUE-401’s TGF-β/IL-2 bifunctional design, reporting TGF-β–dependent suppression of proinflammatory cells, prevention of B cell plasma differentiation, NK cell modulation, and expansion of regulatory T cells.
Cue Biopharma (Nasdaq: CUE) reported preclinical safety and tolerability data for lead candidate CUE-401 on Feb 17, 2026. Two non-GLP studies in mice (n=24) and non-human primates (n=6) used step-up IV dosing; all core dose levels were well tolerated with no adverse events observed.
Follow-up NHP repeat dosing showed better tolerability at 1 mg/kg versus 3 mg/kg. Management said an IND filing for CUE-401 is planned in upcoming months.
Cue Biopharma (Nasdaq: CUE) appointed Lucinda Warren as Chief Financial and Business Officer, effective Feb 9, 2026. Ms. Warren has served as Cue’s chief business officer since Sept 2024 and brings 30+ years of global pharma and biotech experience.
Management expects Warren to help advance CUE-401, the company’s lead autoimmune asset, toward clinical development while overseeing financial and business strategy.
Cue Biopharma (Nasdaq: CUE) announced the pricing of an underwritten public offering to raise approximately $10 million in gross proceeds.
The offering consists of 35,714,286 shares of common stock (or pre-funded warrants in lieu) sold together with accompanying common stock warrants to purchase 17,857,143 shares at a combined public offering price of $0.28 per unit (pre-funded warrant units at $0.279). Each warrant has a $0.30 exercise price, is exercisable immediately, and expires five years from issuance.
The offering is expected to close on or about December 22, 2025, subject to customary closing conditions, and underwriters have a 30-day option to purchase up to an additional 5,357,140 shares and/or warrants to purchase 2,678,570 shares.
Cue Biopharma (Nasdaq: CUE) announced on December 18, 2025 that it is commencing an underwritten public offering of its common stock (or pre-funded warrants) together with accompanying warrants to purchase common stock.
The company said it will grant underwriters a 30-day option to purchase up to an additional 15% of the shares and/or warrants. The offering is subject to market and other conditions and will be made by a prospectus supplement to the company’s effective Form S-3 registration statement (File No. 333-271786).
ImmunoScape (CUE) announced an exclusive in-licensing deal with Cue Biopharma (Nasdaq: CUE) on November 13, 2025 to combine Cue's clinical-stage Immuno-STAT® molecules with ImmunoScape’s precision TCR therapy in a novel "Seed-and-Boost" approach for solid tumors.
The program targets the WT1 antigen across multiple solid tumors and hematologic malignancies, has compelling preclinical efficacy, and plans IND-enabling studies to enable clinical trials by 2027. Leadership updates include board appointments of Usman Azam and Adrian Bot, and SAB appointment of Pamela Munster. The platform aims to enable in vivo expansion of tumor-targeting T cells while limiting systemic IL-2 toxicity.
Cue Biopharma (Nasdaq: CUE) reported Q3 2025 results and business highlights on November 12, 2025. Key items: a strategic collaboration and license with ImmunoScape including $15M upfront cash (scheduled $10M in Q4 2025, $5M in Nov 2026) plus a 40% equity stake; leadership transition naming Usman Azam CEO effective Sept 29; clinical update reporting a confirmed 50% ORR and new complete response in the Phase 1 CUE-101 + pembrolizumab trial, with 12‑month OS 88% and median OS 32.7 months.
Quarterly finance highlights: collaboration revenue $2.1M, R&D $4.8M (down from $9.4M), G&A $4.9M (up from $2.9M), net loss $7.45M, and cash and equivalents $11.7M as of Sept 30, 2025.